Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 19, 2023 - Issue 3
Submit an article Journal homepage
1,166
Views
2
CrossRef citations to date
0
Altmetric
Coronavirus

Safety and immunogenicity of primary vaccination with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: Two randomized, observer-blinded, placebo-controlled and dose-escalation phase 1 clinical trials

Gui-Ling Chena Shulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, Hangzhou, Zhejiang, People’s Republic of ChinaView further author information
,
Yuan-Zheng Qiub CSPC Megalith Biopharmaceutical Co. Ltd, Shijiazhuang, Hebei, People’s Republic of ChinaView further author information
,
Kai-Qi Wua Shulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, Hangzhou, Zhejiang, People’s Republic of ChinaView further author information
,
Ying Wua Shulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, Hangzhou, Zhejiang, People’s Republic of ChinaView further author information
,
Yuan-Hui Wangc Department of Clinical Pharmacology, Sir Run Run Hospital, Nanjing Medical University, Nanjing, Jiangsu, People’s Republic of ChinaView further author information
,
Yu-Ying Zoub CSPC Megalith Biopharmaceutical Co. Ltd, Shijiazhuang, Hebei, People’s Republic of ChinaView further author information
,
Cong-Gao Penga Shulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, Hangzhou, Zhejiang, People’s Republic of ChinaView further author information
,
Jie Zhaoa Shulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, Hangzhou, Zhejiang, People’s Republic of ChinaView further author information
,
Chang Suc Department of Clinical Pharmacology, Sir Run Run Hospital, Nanjing Medical University, Nanjing, Jiangsu, People’s Republic of ChinaView further author information
,
Jun-Heng Mac Department of Clinical Pharmacology, Sir Run Run Hospital, Nanjing Medical University, Nanjing, Jiangsu, People’s Republic of ChinaView further author information
,
Shao-Nan Nib CSPC Megalith Biopharmaceutical Co. Ltd, Shijiazhuang, Hebei, People’s Republic of ChinaView further author information
,
Xing Wangb CSPC Megalith Biopharmaceutical Co. Ltd, Shijiazhuang, Hebei, People’s Republic of ChinaView further author information
,
Ting-Han Jina Shulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, Hangzhou, Zhejiang, People’s Republic of ChinaView further author information
,
Qi Jianga Shulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, Hangzhou, Zhejiang, People’s Republic of ChinaView further author information
,
Tong Guoa Shulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, Hangzhou, Zhejiang, People’s Republic of ChinaView further author information
,
Yan Xuc Department of Clinical Pharmacology, Sir Run Run Hospital, Nanjing Medical University, Nanjing, Jiangsu, People’s Republic of ChinaView further author information
,
Chao-Chao Huangc Department of Clinical Pharmacology, Sir Run Run Hospital, Nanjing Medical University, Nanjing, Jiangsu, People’s Republic of ChinaView further author information
,
Qing Zhangc Department of Clinical Pharmacology, Sir Run Run Hospital, Nanjing Medical University, Nanjing, Jiangsu, People’s Republic of ChinaView further author information
,
Kai-Li Liub CSPC Megalith Biopharmaceutical Co. Ltd, Shijiazhuang, Hebei, People’s Republic of ChinaView further author information
,
Li Jib CSPC Megalith Biopharmaceutical Co. Ltd, Shijiazhuang, Hebei, People’s Republic of ChinaView further author information
,
Han-Yu Yangb CSPC Megalith Biopharmaceutical Co. Ltd, Shijiazhuang, Hebei, People’s Republic of ChinaView further author information
,
Chun-Lei Lib CSPC Megalith Biopharmaceutical Co. Ltd, Shijiazhuang, Hebei, People’s Republic of ChinaCorrespondence[email protected]
View further author information
,
Yu-Wen Suc Department of Clinical Pharmacology, Sir Run Run Hospital, Nanjing Medical University, Nanjing, Jiangsu, People’s Republic of China;d National Vaccine Innovation Platform, School of Pharmacy, Nanjing Medical University, Nanjing, Jiangsu, People’s Republic of ChinaCorrespondence[email protected]
View further author information
,
Xiang Luc Department of Clinical Pharmacology, Sir Run Run Hospital, Nanjing Medical University, Nanjing, Jiangsu, People’s Republic of China;d National Vaccine Innovation Platform, School of Pharmacy, Nanjing Medical University, Nanjing, Jiangsu, People’s Republic of ChinaCorrespondence[email protected]
View further author information
&
Lan-Juan Lie State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People’s Republic of ChinaCorrespondence[email protected]
View further author information
 show all
Article: 2285089 | Received 28 Sep 2023, Accepted 15 Nov 2023, Published online: 18 Dec 2023

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.